Gilead Sciences, Inc. (GILD) Tops Q2 EPS by 63c; Boosts FY14 Revenue Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
Gilead Sciences (GILD) PT Raised to $111 at Piper Jaffray Post Q2
July 24, 2014 10:40 AM EDTPiper Jaffray analyst Joshua Schimmer reiterated an Overweight rating and boosted his price target on Gilead Sciences (NASDAQ: GILD) to $111.00 (from $106.00) following better-than-expected Q2 results and outlook.
Schimmer commented, "Yet again, GILD easily surpassed top/bottom line numbers but contracted LT growth... More
Gilead Sciences (GILD) PT Lifted to $165 at BMO Capital on Strong Q2
July 24, 2014 6:40 AM EDTBMO Capital analyst Jim Birchenough, M.D.boosted his price target on Outperform-rated Gilead Sciences (NASDAQ: GILD) to $165.00 (from $120.00) following Q2 results.
Birchenough comments, "With SOVALDI continuing to set sales records on a background of incomplete insurance coverage in the U.S.,... More
About 9,000 Hep C patients have been cured with Sovaldi to date - Gilead (GILD)
July 23, 2014 4:48 PM EDTGilead Sciences (NASDAQ: GILD) said about 9,000 Hep C patients have been cured with Sovaldi to date
... MoreGilead Sciences (GILD) to Resume Trading at 4:25PM ET Following Strong Results
July 23, 2014 4:22 PM EDTGilead Sciences (NASDAQ: GILD) set to resume trading at 4:25PM ET following strong Q2 results and outlook.
... MoreGilead Sciences (GILD) trading halted with news pending
July 23, 2014 4:04 PM EDTGilead Sciences (NASDAQ: GILD) trading halted with news pending.
... More